GlassScriptPhysician profile
Ravi Kumar Chimalakonda
NPI 1871795484
$1,589.28
in general payments reported to CMS, 2019-2025
22 companies · $639 in 2025
The $639 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $39.96 · 2021: $174 · 2022: $196 · 2023: $172 · 2024: $259 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $352.17 | 2019-2023 | |
| Abbvie INC. | $309.98 | 2024-2025 | |
| Novo Nordisk INC | $167.99 | 2021-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $145.59 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $138.17 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $115.06 | 2020-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.66 | 2025 | Xifaxan |
| Corcept Therapeutics | $29.19 | 2025 | Korlym |
| Baxter Healthcare | $28.20 | 2022 | |
| Inspire Medical Systems, INC. | $24.45 | 2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $23.45 | 2023 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $23.32 | 2024 | Injectafer |
| Soleno Therapeutics, INC. | $23.24 | 2025 | Vykat Xr |
| Mylan Specialty L.P. | $22.39 | 2024 | Yupelri |
| Nevro Corp. | $18.91 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $18.90 | 2023 | |
| Glaxosmithkline, LLC. | $17.71 | 2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $17.52 | 2022 | |
| Viatris Specialty LLC | $17.35 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $16.91 | 2023 | Eliquis |
| Lilly USA, LLC | $11.13 | 2021 | |
| Cvrx, INC. | $10.99 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Chimalakonda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.